[lcus_masonry_article]<\/p>\n
Embodiment thirteen in U.S. patent application 19\/540,453 is a disease cure research framework. It encompasses research and development for cures and treatments for a plurality of diseases (e.g., 300) that typically do not use opioids. Diseases are organized into categories: infectious, cardiovascular, respiratory, gastrointestinal, endocrine, neurological, musculoskeletal, dermatological, hematologic, psychiatric, renal, hepatic, autoimmune, genetic, oncological, and metabolic. The framework supports documentation and NDA\/payment terms for each research stream.<\/p>\n
This is the umbrella under which the diabetes, Alzheimer’s, and Parkinson’s cure discovery methods sit. The framework does not list every disease by name in the patent but defines the categories and the principle: non-opioid, category-based, with support for documentation and commercial terms (NDA, payment) per research stream. That makes it possible to add new disease pipelines within the same intellectual and legal structure.<\/p>\n
Specifying that the framework focuses on diseases that do not typically use opioids draws a clear line: the portfolio is oriented toward curative and non-addictive therapeutic pathways. It also avoids overlap with opioid-based pain or palliative research. For investors and partners, the framework signals a structured approach to many indications with a consistent philosophy.<\/p>\n
Figure 13 in the specification is a flowchart: header, categories, output. The application (19\/540,453) was filed February 13, 2026; the USPTO payment receipt confirms receipt and payment (Confirmation # 1134).<\/p>\n
Source: US Patent Application 19\/540,453, Section 8.13 and Figure 13.<\/em><\/p>\n [\/lcus_masonry_article]<\/p>\n <\/p>\n